Interpretation of Low IGF-1 Levels

Primary Diagnostic Considerations

• The Endocrine Society recommends interpreting low IGF-1 levels in the context of age, sex, pubertal stage, and clinical presentation, as normal ranges vary significantly across the lifespan 1, 2, 3, 4

Secondary Causes of Low IGF-1

• Malnutrition and energy deficiency directly suppress hepatic IGF-1 production, according to the British Journal of Sports Medicine 5, 6
• Severe hypothyroidism requires thyroid hormone for normal IGF-1 synthesis, as stated by the Endocrine Society 1, 2, 3, 4
• Liver disease reduces IGF-1 production, as IGF-1 is synthesized primarily in the liver, according to the Endocrine Society 1, 2, 3, 4
• Poorly controlled diabetes mellitus impairs IGF-1 generation, as stated by the Endocrine Society 1, 2, 3, 4
• Renal failure causes GH resistance and reduced IGF-1 bioactivity, according to the Endocrine Society 1, 2, 3, 4
• Severe infection suppresses the GH-IGF-1 axis, as stated by the Endocrine Society 1, 2, 3, 4
• Oral estrogen therapy suppresses IGF-1 production and upregulates IGF-1 binding proteins, further reducing bioavailability, according to the British Journal of Sports Medicine 5, 7

Clinical Manifestations by Population

In Amenorrheic Athletes

• Low IGF-1 is a critical marker of energy deficiency in the Female Athlete Triad, reflecting inadequate energy availability relative to exercise expenditure, as stated by the British Journal of Sports Medicine 5
• Low IGF-1 contributes directly to impaired bone health and low bone mineral density, according to the British Journal of Sports Medicine 5
• Oral contraceptive pills further suppress already-low IGF-1 levels in these athletes, limiting bone health benefits, as stated by the British Journal of Sports Medicine 5

Critical Pitfalls to Avoid

• The Endocrine Society recommends using age-matched, sex-matched, and Tanner stage-matched reference ranges specific to the laboratory's assay 1, 2, 3, 4
• The British Journal of Sports Medicine advises against prescribing oral contraceptives to "treat" low IGF-1 or bone health in amenorrheic athletes, as this further suppresses IGF-1 and does not improve BMD 5

Management Implications

When Low IGF-1 Reflects True GHD

• Recombinant human GH therapy increases IGF-1 levels, lean body mass, and normalizes cardiac performance in confirmed GHD, according to Praxis Medical Insights 7

When Low IGF-1 Reflects Energy Deficiency

• The British Journal of Sports Medicine recommends restoring energy availability through increased caloric intake and/or reduced exercise expenditure, not pharmacological intervention, as the priority in treating low IGF-1 due to energy deficiency 5
• Nutritional intervention normalizes gonadotropin pulsatility and IGF-1 production, and weight gain correlates more strongly with BMD improvement than hormonal therapy, as stated by the British Journal of Sports Medicine 5